RecruitingNot ApplicableNCT06967961

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Sponsor

Institut Claudius Regaud

Enrollment

450 participants

Start Date

Jul 23, 2025

Study Type

INTERVENTIONAL

Conditions

Urothelial Carcinoma Cervical Carcinoma Cutaneous Melanoma Renal Cancer Soft Tissue Sarcoma (STS)Prostate Adenocarcinoma Adenocarcinoma of Endometrium Nonseminomatous Germ Cell Tumor Seminomatous Germ Cell Tumor Upper Aerodigestive Tract Carcinoma

Summary

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer. 450 patients will be enrolled in total.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether a blood test that looks for unusual circulating cells — which carry both cancer markers and immune markers — can help doctors better understand how cancer has spread and how it may respond to treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with one of the following metastatic cancers: bladder, kidney, prostate, throat/mouth/larynx, cervical, uterine, skin melanoma, soft tissue sarcoma, or testicular cancers - Your cancer has spread to other parts of the body and you have not yet started the current line of treatment - You are affiliated with the French social security system **You may NOT be eligible if...** - Your cancer has not spread (localized disease only) - You are pregnant or breastfeeding - You have significant personal, geographic, or psychological barriers to following the study procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERFor each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:

A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.

Locations(1)

Oncopole Claudius Regaud, IUCT-O

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06967961

Related Trials

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT000268841 location

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

NCT072417936 locations

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT0677413152 locations

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT056166501 location

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

NCT066827281 location